• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Nuvation Bio Inc.

    10/18/24 4:15:55 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NUVB alert in real time by email
    SC 13D/A 1 d892626dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 13D

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 2)*

     

     

    Nuvation Bio, Inc.

    (Name of Issuer)

     

     

    Class A Common Stock

    (Title of Class of Securities)

    67080N 101

    (CUSIP Number)

    OTELLO STAMPACCHIA

    OMEGA FUND V, L.P.

    888 BOYLSTON ST., STE. 1111

    BOSTON, MA 02199

    TELEPHONE: 617-502-6538

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    September 4, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 67080N 101   13D

     

     1.   

     Name of Reporting Persons

     

     Omega Fund V, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒(1)

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (see instructions)

     

     WC

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     13,072,340 shares of Class A Common Stock (2)

        8.   

     Shared Voting Power

     

     0

        9.   

     Sole Dispositive Power

     

     13,072,340 shares of Class A Common Stock (2)

       10.   

     Shared Dispositive Power

     

     0

    11.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     13,072,340 shares of Class A Common Stock (2)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row 11

     

     3.9% (2)

    14.  

     Type of Reporting Person (see instructions)

     

     PN

     

    (1)

    This Schedule 13D is filed by Omega Fund V, L.P. (“Omega Fund”), Omega Fund V GP, L.P. (“Omega GP”), Omega Fund V GP Manager, Ltd. (“Omega Ltd”), Claudio Nessi (“Nessi”) and Otello Stampacchia (“Stampacchia”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Nessi and Stampacchia are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13D. Each of Nessi and Stampacchia expressly disclaims beneficial ownership of the securities reported herein, except to the extent of his or her pecuniary interest therein, if any.

    (2)

    This percentage set forth on the cover sheets is calculated based on 333,780,289 shares of Class A Common Stock as of September 4, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on September 5, 2024.


    CUSIP No. 67080N 101   13D

     

     1.   

     Name of Reporting Persons

     

     Omega Fund V GP, L.P.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒(1)

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (see instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     13,072,340 shares of Class A Common Stock (2)

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     13,072,340 shares of Class A Common Stock (2)

    11.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     13,072,340 shares of Class A Common Stock (2)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row 11

     

     3.9% (2)

    14.  

     Type of Reporting Person (see instructions)

     

     PN

     

    (1)

    This Schedule 13D is filed by Omega Fund V, L.P. (“Omega Fund”), Omega Fund V GP, L.P. (“Omega GP”), Omega Fund V GP Manager, Ltd. (“Omega Ltd”), Claudio Nessi (“Nessi”) and Otello Stampacchia (“Stampacchia”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Nessi and Stampacchia are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13D. Each of Nessi and Stampacchia expressly disclaims beneficial ownership of the securities reported herein, except to the extent of his or her pecuniary interest therein, if any.

    (2)

    This percentage set forth on the cover sheets is calculated based on 333,780,289 shares of Class A Common Stock as of September 4, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on September 5, 2024.


    CUSIP No. 67080N 101   13D

     

     1.   

     Name of Reporting Persons

     

     Omega Fund V GP Manager, Ltd.

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒(1)

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (see instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     13,072,340 shares of Class A Common Stock (2)

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     13,072,340 shares of Class A Common Stock (2)

    11.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     13,072,340 shares of Class A Common Stock (2)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row 11

     

     3.9% (2)

    14.  

     Type of Reporting Person (see instructions)

     

     OO

     

    (1)

    This Schedule 13D is filed by Omega Fund V, L.P. (“Omega Fund”), Omega Fund V GP, L.P. (“Omega GP”), Omega Fund V GP Manager, Ltd. (“Omega Ltd”), Claudio Nessi (“Nessi”) and Otello Stampacchia (“Stampacchia”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Nessi and Stampacchia are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13D. Each of Nessi and Stampacchia expressly disclaims beneficial ownership of the securities reported herein, except to the extent of his or her pecuniary interest therein, if any.

    (2)

    This percentage set forth on the cover sheets is calculated based on 333,780,289 shares of Class A Common Stock as of September 4, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on September 5, 2024.


    CUSIP No. 67080N 101   13D

     

     

     1.   

     Name of Reporting Persons

     

     Claudio Nessi

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒(1)

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (see instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Switzerland

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     13,072,340 shares of Class A Common Stock (2)

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     13,072,340 shares of Class A Common Stock (2)

    11.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     13,072,340 shares of Class A Common Stock (2)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row 11

     

     3.9% (2)

    14.  

     Type of Reporting Person (see instructions)

     

     IN

     

    (1)

    This Schedule 13D is filed by Omega Fund V, L.P. (“Omega Fund”), Omega Fund V GP, L.P. (“Omega GP”), Omega Fund V GP Manager, Ltd. (“Omega Ltd”), Claudio Nessi (“Nessi”) and Otello Stampacchia (“Stampacchia”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Nessi and Stampacchia are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13D. Each of Nessi and Stampacchia expressly disclaims beneficial ownership of the securities reported herein, except to the extent of his or her pecuniary interest therein, if any.

    (2)

    This percentage set forth on the cover sheets is calculated based on 333,780,289 shares of Class A Common Stock as of September 4, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on September 5, 2024.


    CUSIP No. 67080N 101   13D

     

     

     1.   

     Name of Reporting Persons

     

     Otello Stampacchia

     2.  

     Check the Appropriate Box if a Member of a Group (see instructions)

     (a) ☐  (b) ☒(1)

     

     3.  

     SEC USE ONLY

     

     4.  

     Source of Funds (see instructions)

     

     AF

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Italy

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.    

     Sole Voting Power

     

     0

        8.   

     Shared Voting Power

     

     13,072,340 shares of Class A Common Stock (2)

        9.   

     Sole Dispositive Power

     

     0

       10.   

     Shared Dispositive Power

     

     13,072,340 shares of Class A Common Stock (2)

    11.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     13,072,340 shares of Class A Common Stock (2)

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row 11

     

     3.9% (2)

    14.  

     Type of Reporting Person (see instructions)

     

     IN

     

    (1)

    This Schedule 13D is filed by Omega Fund V, L.P. (“Omega Fund”), Omega Fund V GP, L.P. (“Omega GP”), Omega Fund V GP Manager, Ltd. (“Omega Ltd”), Claudio Nessi (“Nessi”) and Otello Stampacchia (“Stampacchia”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Nessi and Stampacchia are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13D. Each of Nessi and Stampacchia expressly disclaims beneficial ownership of the securities reported herein, except to the extent of his or her pecuniary interest therein, if any.

    (2)

    This percentage set forth on the cover sheets is calculated based on 333,780,289 shares of Class A Common Stock as of September 4, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on September 5, 2024.


    CUSIP No. 67080N 101   13D

     

    The following constitutes Amendment No. 2 to the Schedule 13D filed by the undersigned (“Amendment No. 2”). This Amendment No. 2 amends the Schedule 13D as specifically set forth herein.

    Item 5. Interest in Securities of the Issuer

    Items 5(a)-(e) are hereby amended and restated to read as follows:

    (a), (b) The aggregate number and percentage of Class A Common Stock of the Issuer owned by each Reporting Person are based upon 333,780,289 shares of Class A Common Stock as of September 4, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on September 5, 2024.

    The Reporting Persons may be deemed to beneficially own an aggregate of 13,072,340 shares of Class A Common Stock. This aggregate number represents approximately 3.9% of the total Shares of Class A Common Stock currently outstanding.

    Each Reporting Person may be deemed to beneficially own the shares set forth below:

     

    Omega Fund

         —        13,072,340  

    Omega GP

         —        13,072,340  

    Omega Ltd

         —        13,072,340  

    Nessi

         —        13,072,340  

    Stampacchia

         —        13,072,340  

    The Omega Fund has the sole power to vote and dispose of 13,072,340 Shares of Class A Common Stock as a result of its direct beneficial ownership of 13,072,340 Shares of Class A Common Stock. Omega GP, Omega Ltd, Nessi and Stampacchia may be deemed, on an aggregate basis, to have shared power to vote and dispose of 13,072,340 Shares of Class A Common Stock as a result of their deemed beneficial ownership of 13,072,340 Shares of Class A Common Stock.

    Pursuant to Rule 13d-4 of the Act, each of Nessi and Stampacchia expressly disclaims beneficial ownership of the securities reported herein, except to the extent of his or her pecuniary interest therein, if any.

    (c) Information concerning transactions in the shares of Class A Common Stock effected within last 60 days by the Reporting Persons is set forth below.

     

    Reporting Person Who Effected The Transaction

       Date of
    Transaction
         Number
    of Shares
         Type of
    Security
       Average Price
    Per Share
         Where and How
    the Transaction
    was Effected

    Omega Fund

         07/12/2024        85,082      Class A
    Common Stock
       $ 3.5112      Open market
    sale on Nasdaq

    Omega Fund

         07/16/2024        8,493      Class A
    Common Stock
       $ 3.5000      Open market
    sale on Nasdaq

    Omega Fund

         07/24/2024        109,929      Class A
    Common Stock
       $ 3.5551      Open market
    sale on Nasdaq

    (d) Not applicable.

    (e) As of September 4, 2024, the Reporting Persons ceased to be beneficial owners of more than five percent of the Issuer’s Class A Common Stock.


    CUSIP No. 67080N 101   13D

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: October 18, 2024

     

    OMEGA FUND V, L.P.
    BY: Omega Fund V GP, L.P.
    ITS: GENERAL PARTNER
    BY: Omega Fund V GP Manager, Ltd.
    ITS: GENERAL PARTNER
    By:  

    /s/ * Deirdre A. Cunnane, as Attorney-in-Fact

      Director
    OMEGA FUND V GP, L.P.
    BY: Omega Fund V GP Manager, Ltd.
    ITS: GENERAL PARTNER
    By:  

    /s/ * Deirdre A. Cunnane, as Attorney-in-Fact

      Director
    OMEGA FUND V GP MANAGER, LTD.
    By:  

    /s/ * Deirdre A. Cunnane, as Attorney-in-Fact

      Director

    /s/ * Deirdre A. Cunnane, as Attorney-in-Fact

    Claudio Nessi

    /s/ * Deirdre A. Cunnane, as Attorney-in-Fact

    Otello Stampacchia
    Get the next $NUVB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUVB

    DatePrice TargetRatingAnalyst
    4/23/2025$6.00Mkt Outperform
    Citizens JMP
    3/27/2024$1.40 → $10.00Hold → Buy
    Jefferies
    3/26/2024$5.00Neutral → Buy
    BTIG Research
    1/6/2023$5.00 → $2.00Buy → Hold
    Jefferies
    8/2/2022$8.00 → $2.50Outperform → Market Perform
    BMO Capital Markets
    8/2/2022Buy → Neutral
    BTIG Research
    5/4/2022$14.00Buy
    H.C. Wainwright
    10/15/2021$16.00Buy
    BTIG Research
    More analyst ratings

    $NUVB
    SEC Filings

    See more
    • SEC Form 10-Q filed by Nuvation Bio Inc.

      10-Q - Nuvation Bio Inc. (0001811063) (Filer)

      5/7/25 4:20:58 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Nuvation Bio Inc.

      8-K - Nuvation Bio Inc. (0001811063) (Filer)

      5/7/25 4:15:24 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Nuvation Bio Inc.

      DEF 14A - Nuvation Bio Inc. (0001811063) (Filer)

      4/8/25 4:45:37 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nuvation Bio Inc.

      SC 13G/A - Nuvation Bio Inc. (0001811063) (Subject)

      11/12/24 10:32:11 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Nuvation Bio Inc.

      SC 13D/A - Nuvation Bio Inc. (0001811063) (Subject)

      10/18/24 4:15:55 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Nuvation Bio Inc.

      SC 13D - Nuvation Bio Inc. (0001811063) (Subject)

      9/10/24 4:51:38 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Hung David bought $820,220 worth of shares (500,000 units at $1.64), increasing direct ownership by 0.86% to 58,781,054 units (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      4/8/25 9:30:51 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mashal Robert bought $166,985 worth of shares (100,000 units at $1.67) (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      4/3/25 4:05:07 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mashal Robert bought $220,000 worth of shares (100,000 units at $2.20) (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      10/10/24 4:33:51 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Financials

    Live finance-specific insights

    See more
    • Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

      New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) under U.S. Food and Drug Administration (FDA) Priority Review; Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025 Published pooled results from pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib in Journal of Clinical Oncology demonstrating high response rates, durable responses, and a favorable safety profile Strong balance sheet with cash, cash equivalents, and marketable securities of $461.7 million as of March 31, 2025 Company to host a conference call today at 4:30 p.m. ET Nuvation Bio Inc. (NYSE:NUVB), a global oncology company tackling some

      5/7/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

      Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter of 2025 on Wednesday, May 7, 2025. Company executives will provide an overview of its programs, summarize its commercial strategy for taletrectinib, and review financial results beginning at 4:30 p.m. ET. The U.S. Food and Drug Administration assigned taletrectinib's New Drug Application with a Prescription Drug User Fee Act goal date of June 23, 2025. Investors and the general public are invited to listen to a live webcast of the call at https://investors.nuvationbio.com/investors/. Materials related to the call will

      4/22/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

      Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025 Acquisition adds taletrectinib, a next-generation, potentially best-in-class ROS1 inhibitor with Breakthrough Therapy Designations currently completing two pivotal studies for the treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC) Acquisition also adds safusidenib, a potentially best-in-class mutant IDH1 inhibitor currently being evaluated in a global Phase 2 study of patients with grades 2 and 3 IDH1-mutant glioma All-stock transaction preserves Nuvation Bio's robust cash balance and enables development of both new

      3/25/24 7:00:00 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

      New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) under U.S. Food and Drug Administration (FDA) Priority Review; Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025 Published pooled results from pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib in Journal of Clinical Oncology demonstrating high response rates, durable responses, and a favorable safety profile Strong balance sheet with cash, cash equivalents, and marketable securities of $461.7 million as of March 31, 2025 Company to host a conference call today at 4:30 p.m. ET Nuvation Bio Inc. (NYSE:NUVB), a global oncology company tackling some

      5/7/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio to Present at The Citizens Life Sciences Conference

      Nuvation Bio Inc. (NYSE:NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today announced that Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at The Citizens Life Sciences Conference on Thursday, May 8, 2025, at 10:00 a.m. ET in New York, NY. A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.nuvationbio.com/investors/. An archived recording will be available for 90 days following each event. About Nuvation Bio Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment by developing therapies

      5/1/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

      Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter of 2025 on Wednesday, May 7, 2025. Company executives will provide an overview of its programs, summarize its commercial strategy for taletrectinib, and review financial results beginning at 4:30 p.m. ET. The U.S. Food and Drug Administration assigned taletrectinib's New Drug Application with a Prescription Drug User Fee Act goal date of June 23, 2025. Investors and the general public are invited to listen to a live webcast of the call at https://investors.nuvationbio.com/investors/. Materials related to the call will

      4/22/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF MEDICAL OFFICER Liu Dongfang exercised 20,000 shares at a strike of $1.94 and sold $50,024 worth of shares (20,000 units at $2.50) (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      5/6/25 4:05:06 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Hung David bought $820,220 worth of shares (500,000 units at $1.64), increasing direct ownership by 0.86% to 58,781,054 units (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      4/8/25 9:30:51 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mashal Robert bought $166,985 worth of shares (100,000 units at $1.67) (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      4/3/25 4:05:07 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Leadership Updates

    Live Leadership Updates

    See more
    • Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer

      Global leader with proven financial, operational, and commercial expertise joins Nuvation Bio as the company prepares to transition into a commercial-stage organization Nuvation Bio Inc. (NYSE:NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw strategic segments including commercial systems, multicha

      10/7/24 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

      Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting First patient treated in a Phase 1/2 study of NUV-1511, the company's first drug-drug conjugate (DDC) to enter the clinic, for the treatment of various advanced solid tumors Strong balance sheet with cash, cash equivalents, and marketable securities of $597.0 million as of March 31, 2024 Nuvation Bio Inc. (NYSE:NUVB), a late-stage

      5/14/24 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

      Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches Pending acquisition of AnHeart Therapeutics and expanded leadership strongly positions Nuvation Bio to potentially become a commercial organization by the end of 2025 Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company's commercial strategy and operations, including marketing, sales, and market access. "We are t

      3/28/24 8:00:00 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NUVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on Nuvation Bio with a new price target

      Citizens JMP initiated coverage of Nuvation Bio with a rating of Mkt Outperform and set a new price target of $6.00

      4/23/25 8:17:12 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio upgraded by Jefferies with a new price target

      Jefferies upgraded Nuvation Bio from Hold to Buy and set a new price target of $10.00 from $1.40 previously

      3/27/24 8:16:27 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio upgraded by BTIG Research with a new price target

      BTIG Research upgraded Nuvation Bio from Neutral to Buy and set a new price target of $5.00

      3/26/24 7:48:54 AM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care